Abstract
9044 Background: Phase I testing of the hu14.18-IL2 immunocytokine (IC), a mAb reactive with GD2 disialoganglioside, linked to IL2, in patients (pts) with melanoma showed immune activation, reversi...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have